Marksans Pharma Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 13, 2025, 5:53 am

Market Cap	11,780 Cr.
Current Price	260
High / Low	359/157
Stock P/E	31.0
Book Value	54.4
Dividend Yield	0.23 %
ROCE	20.1 %
ROE	16.8 %
Face Value	1.00
PEG Ratio	4.34

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Marksans Pharma Ltd

Competitors of Marksans Pharma Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	142 Cr.	101	247/84.3	27.6	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	5.27 Cr.	2.76	4.33/2.50		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	41.6 Cr.	56.0	94.9/44.5		8.73	0.00 %	41.5 %	14.4 %	10.0
Gujarat Inject (Kerala) Ltd	32.1 Cr.	21.9	29.1/13.1	31.4	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	18,987.75 Cr	1,190.31		92.21	194.72	0.30%	16.67%	15.20%	6.18

All Competitor Stocks of Marksans Pharma Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	418	434	453	480	486	500	531	586	560	591	642	682	708
Expenses	354	361	372	403	376	398	417	453	450	462	506	543	583
Operating Profit	64	73	80	77	110	102	114	133	110	128	136	139	126
OPM %	15%	17%	18%	16%	23%	20%	21%	23%	20%	22%	21%	20%	18%
Other Income	15	16	14	18	11	10	19	5	17	15	11	28	17
Interest	5	2	3	2	2	2	2	3	5	3	3	3	3
Depreciation	21	11	14	13	14	14	18	22	21	20	20	21	23
Profit before tax	53	76	78	79	104	97	114	113	100	120	125	143	116
Tax %	44%	21%	23%	21%	21%	27%	26%	26%	23%	26%	22%	27%	22%
Net Profit	30	60	60	62	83	70	84	83	78	89	98	105	91
EPS in Rs	0.69	1.46	1.51	1.57	1.81	1.52	1.84	1.84	1.73	1.96	2.13	2.31	2.00

Last Updated: May 31, 2025, 8:28 am

Below is a detailed analysis of the quarterly data for Marksans Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 708.00 Cr.. The value appears strong and on an upward trend. It has increased from 682.00 Cr. (Dec 2024) to 708.00 Cr., marking an increase of 26.00 Cr..
For Expenses, as of Mar 2025, the value is 583.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 543.00 Cr. (Dec 2024) to 583.00 Cr., marking an increase of 40.00 Cr..
For Operating Profit, as of Mar 2025, the value is 126.00 Cr.. The value appears to be declining and may need further review. It has decreased from 139.00 Cr. (Dec 2024) to 126.00 Cr., marking a decrease of 13.00 Cr..
For OPM %, as of Mar 2025, the value is 18.00%. The value appears to be declining and may need further review. It has decreased from 20.00% (Dec 2024) to 18.00%, marking a decrease of 2.00%.
For Other Income, as of Mar 2025, the value is 17.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Dec 2024) to 17.00 Cr., marking a decrease of 11.00 Cr..
For Interest, as of Mar 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 3.00 Cr..
For Depreciation, as of Mar 2025, the value is 23.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 21.00 Cr. (Dec 2024) to 23.00 Cr., marking an increase of 2.00 Cr..
For Profit before tax, as of Mar 2025, the value is 116.00 Cr.. The value appears to be declining and may need further review. It has decreased from 143.00 Cr. (Dec 2024) to 116.00 Cr., marking a decrease of 27.00 Cr..
For Tax %, as of Mar 2025, the value is 22.00%. The value appears to be improving (decreasing) as expected. It has decreased from 27.00% (Dec 2024) to 22.00%, marking a decrease of 5.00%.
For Net Profit, as of Mar 2025, the value is 91.00 Cr.. The value appears to be declining and may need further review. It has decreased from 105.00 Cr. (Dec 2024) to 91.00 Cr., marking a decrease of 14.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 2.00. The value appears to be declining and may need further review. It has decreased from 2.31 (Dec 2024) to 2.00, marking a decrease of 0.31.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 3:32 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	438	630	797	893	767	913	1,000	1,134	1,376	1,491	1,852	2,177	2,474
Expenses	369	512	612	757	722	834	868	942	1,037	1,232	1,513	1,719	1,962
Operating Profit	69	118	185	136	45	78	132	192	340	259	340	459	513
OPM %	16%	19%	23%	15%	6%	9%	13%	17%	25%	17%	18%	21%	21%
Other Income	4	4	3	9	7	8	5	0	7	42	59	50	70
Interest	15	19	16	10	7	10	10	9	8	8	9	11	13
Depreciation	16	16	16	28	30	27	23	27	36	45	52	74	82
Profit before tax	44	86	156	107	15	50	104	157	302	248	338	424	488
Tax %	-12%	15%	28%	23%	24%	28%	23%	23%	21%	25%	21%	26%
Net Profit	49	74	112	83	11	36	80	121	239	187	265	315	370
EPS in Rs	1.19	1.87	2.67	1.92	0.22	0.80	1.87	2.95	5.76	4.51	5.88	6.92	8.13
Dividend Payout %	10%	5%	4%	21%	23%	6%	3%	3%	4%	6%	9%	9%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	51.02%	51.35%	-25.89%	-86.75%	227.27%	122.22%	51.25%	97.52%	-21.76%	41.71%	18.87%
Change in YoY Net Profit Growth (%)	0.00%	0.33%	-77.24%	-60.85%	314.02%	-105.05%	-70.97%	46.27%	-119.28%	63.47%	-22.84%

Marksans Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	13%
5 Years:	18%
3 Years:	21%
TTM:	20%

Compounded Profit Growth
10 Years:	13%
5 Years:	26%
3 Years:	27%
TTM:	21%

Stock Price CAGR
10 Years:	16%
5 Years:	53%
3 Years:	80%
1 Year:	63%

Return on Equity
10 Years:	17%
5 Years:	19%
3 Years:	17%
Last Year:	17%

Last Updated: Unknown

Balance Sheet

Last Updated: June 12, 2025, 3:06 pm

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	39	41	41	41	41	41	41	41	41	45	45	45
Reserves	90	326	401	392	430	502	595	846	1,161	1,700	2,020	2,422
Borrowings	173	101	100	110	118	100	30	34	111	123	244	322
Other Liabilities	188	207	180	209	142	160	236	307	323	322	372	451
Total Liabilities	490	676	722	752	731	802	902	1,228	1,636	2,190	2,681	3,240
Fixed Assets	146	166	270	267	279	270	303	309	428	486	776	1,000
CWIP	0	0	0	0	0	0	0	12	3	10	9	9
Investments	0	0	0	0	0	0	0	0	0	1	27	1
Other Assets	344	510	452	484	451	533	599	907	1,205	1,694	1,869	2,230
Total Assets	490	676	722	752	731	802	902	1,228	1,636	2,190	2,681	3,240

Below is a detailed analysis of the balance sheet data for Marksans Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is 45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 45.00 Cr..
For Reserves, as of Mar 2025, the value is 2,422.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,020.00 Cr. (Mar 2024) to 2,422.00 Cr., marking an increase of 402.00 Cr..
For Borrowings, as of Mar 2025, the value is 322.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 244.00 Cr. (Mar 2024) to 322.00 Cr., marking an increase of 78.00 Cr..
For Other Liabilities, as of Mar 2025, the value is 451.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 372.00 Cr. (Mar 2024) to 451.00 Cr., marking an increase of 79.00 Cr..
For Total Liabilities, as of Mar 2025, the value is 3,240.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,681.00 Cr. (Mar 2024) to 3,240.00 Cr., marking an increase of 559.00 Cr..
For Fixed Assets, as of Mar 2025, the value is 1,000.00 Cr.. The value appears strong and on an upward trend. It has increased from 776.00 Cr. (Mar 2024) to 1,000.00 Cr., marking an increase of 224.00 Cr..
For CWIP, as of Mar 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 9.00 Cr..
For Investments, as of Mar 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 27.00 Cr. (Mar 2024) to 1.00 Cr., marking a decrease of 26.00 Cr..
For Other Assets, as of Mar 2025, the value is 2,230.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,869.00 Cr. (Mar 2024) to 2,230.00 Cr., marking an increase of 361.00 Cr..
For Total Assets, as of Mar 2025, the value is 3,240.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,681.00 Cr. (Mar 2024) to 3,240.00 Cr., marking an increase of 559.00 Cr..

Notably, the Reserves (2,422.00 Cr.) exceed the Borrowings (322.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	65	155	31	14	50	27	233	179	99	237	230	207
Cash from Investing Activity +	-4	-33	-123	-21	-39	-13	-60	-45	-84	-259	-141	-49
Cash from Financing Activity +	-29	17	-58	-3	3	-21	-114	-15	80	198	-69	-65
Net Cash Flow	31	138	-150	-10	15	-7	60	118	94	176	21	93

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	69.00	-55.00	84.00	36.00	-65.00	-40.00	32.00	162.00	306.00	148.00	217.00	215.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	109	98	84	89	118	71	64	78	72	97	82	76
Inventory Days	112	102	107	120	151	152	215	155	248	216	192	217
Days Payable	81	83	88	85	129	54	78	71	103	102	91	94
Cash Conversion Cycle	141	118	103	124	140	169	202	163	217	211	183	199
Working Capital Days	37	48	55	95	130	117	133	94	110	138	133	138
ROCE %	43%	37%	44%	23%	4%	10%	18%	25%	38%	23%	22%	21%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoters	48.25%	48.25%	48.25%	48.25%	48.60%	49.00%	43.85%	43.85%	43.85%	43.85%	43.85%	43.87%
FIIs	2.64%	2.59%	3.46%	4.04%	4.06%	4.23%	15.11%	14.90%	15.07%	15.55%	15.57%	18.59%
DIIs	0.53%	0.41%	0.47%	0.94%	0.95%	0.96%	1.46%	3.65%	4.02%	4.76%	5.17%	3.75%
Public	48.58%	48.75%	47.82%	46.77%	46.38%	45.79%	39.57%	37.60%	37.06%	35.81%	35.40%	33.77%
No. of Shareholders	2,01,451	2,14,998	2,20,090	2,21,359	2,17,743	2,13,123	1,98,382	1,88,447	2,07,937	2,37,377	2,54,699	2,35,500

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Quant Small Cap Fund	12,641,259	1.88	210.29	12,641,259	2025-04-22 17:25:27	0%
UTI Aggressive Hybrid Fund	2,078,253	0.46	21.94	2,078,253	2025-04-22 17:25:27	0%
UTI Large & Mid Cap Fund	1,082,611	0.58	11.43	1,082,611	2025-04-22 17:25:27	0%
UTI Retirement Fund	1,049,499	0.28	11.08	1,049,499	2025-04-22 17:25:27	0%
Motilal Oswal Nifty Microcap 250 Index Fund	225,777	0.66	3.76	225,777	2025-04-22 17:25:27	0%
UTI Healthcare Fund	232,711	0.32	2.46	232,711	2025-04-22 17:25:27	0%
Motilal Oswal S&P BSE Healthcare ETF	2,691	0.49	0.04	2,691	2025-04-22 17:25:27	0%
Groww Nifty Total Market Index Fund	557	0.02	0.01	557	2025-04-22 17:25:27	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	1.00	1.00	1.00	1.00	1.00
Basic EPS (Rs.)	6.92	6.41	4.51	5.76	2.86
Diluted EPS (Rs.)	6.92	6.41	4.51	5.76	2.86
Cash EPS (Rs.)	8.59	7.00	5.66	6.71	3.60
Book Value[Excl.RevalReserv]/Share (Rs.)	46.03	38.95	29.88	22.12	15.86
Book Value[Incl.RevalReserv]/Share (Rs.)	46.03	38.95	29.88	22.12	15.86
Revenue From Operations / Share (Rs.)	48.05	40.87	36.42	33.62	27.71
PBDIT / Share (Rs.)	11.23	8.80	7.35	8.46	4.70
PBIT / Share (Rs.)	9.59	7.65	6.25	7.58	4.05
PBT / Share (Rs.)	9.35	7.45	6.05	7.38	3.84
Net Profit / Share (Rs.)	6.95	5.85	4.56	5.83	2.95
NP After MI And SOA / Share (Rs.)	6.92	5.88	4.56	5.83	2.95
PBDIT Margin (%)	23.37	21.52	20.17	25.16	16.97
PBIT Margin (%)	19.96	18.72	17.16	22.53	14.62
PBT Margin (%)	19.45	18.23	16.60	21.95	13.85
Net Profit Margin (%)	14.46	14.32	12.53	17.33	10.64
NP After MI And SOA Margin (%)	14.40	14.37	12.53	17.33	10.64
Return on Networth / Equity (%)	15.19	15.25	15.53	26.90	18.98
Return on Capital Employeed (%)	18.97	18.75	19.93	33.35	24.62
Return On Assets (%)	11.70	12.15	11.39	19.42	13.37
Total Debt / Equity (X)	0.01	0.02	0.03	0.02	0.02
Asset Turnover Ratio (%)	0.89	0.96	1.04	0.73	0.61
Current Ratio (X)	4.78	4.91	3.37	3.02	2.59
Quick Ratio (X)	3.19	3.49	2.18	1.67	1.54
Inventory Turnover Ratio (X)	1.21	1.35	1.30	1.74	1.14
Dividend Payout Ratio (NP) (%)	7.22	3.81	5.47	1.71	24.43
Dividend Payout Ratio (CP) (%)	5.84	3.19	4.41	1.49	20.01
Earning Retention Ratio (%)	92.78	96.19	94.53	98.29	75.57
Cash Earning Retention Ratio (%)	94.16	96.81	95.59	98.51	79.99
Interest Coverage Ratio (X)	45.43	43.67	35.61	43.36	22.02
Interest Coverage Ratio (Post Tax) (X)	29.11	30.07	23.12	30.87	14.81
Enterprise Value (Cr.)	6244.01	2540.86	1577.14	1869.83	507.17
EV / Net Operating Revenue (X)	2.87	1.37	1.06	1.36	0.44
EV / EBITDA (X)	12.27	6.37	5.24	5.40	2.63
MarketCap / Net Operating Revenue (X)	3.15	1.72	1.25	1.49	0.50
Retention Ratios (%)	92.77	96.18	94.52	98.28	75.56
Price / BV (X)	3.33	1.83	1.55	2.31	0.89
Price / Net Operating Revenue (X)	3.15	1.72	1.25	1.49	0.50
EarningsYield	0.04	0.08	0.10	0.11	0.21

After reviewing the key financial ratios for Marksans Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
For Basic EPS (Rs.), as of Mar 24, the value is 6.92. This value is within the healthy range. It has increased from 6.41 (Mar 23) to 6.92, marking an increase of 0.51.
For Diluted EPS (Rs.), as of Mar 24, the value is 6.92. This value is within the healthy range. It has increased from 6.41 (Mar 23) to 6.92, marking an increase of 0.51.
For Cash EPS (Rs.), as of Mar 24, the value is 8.59. This value is within the healthy range. It has increased from 7.00 (Mar 23) to 8.59, marking an increase of 1.59.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 46.03. It has increased from 38.95 (Mar 23) to 46.03, marking an increase of 7.08.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 46.03. It has increased from 38.95 (Mar 23) to 46.03, marking an increase of 7.08.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 48.05. It has increased from 40.87 (Mar 23) to 48.05, marking an increase of 7.18.
For PBDIT / Share (Rs.), as of Mar 24, the value is 11.23. This value is within the healthy range. It has increased from 8.80 (Mar 23) to 11.23, marking an increase of 2.43.
For PBIT / Share (Rs.), as of Mar 24, the value is 9.59. This value is within the healthy range. It has increased from 7.65 (Mar 23) to 9.59, marking an increase of 1.94.
For PBT / Share (Rs.), as of Mar 24, the value is 9.35. This value is within the healthy range. It has increased from 7.45 (Mar 23) to 9.35, marking an increase of 1.90.
For Net Profit / Share (Rs.), as of Mar 24, the value is 6.95. This value is within the healthy range. It has increased from 5.85 (Mar 23) to 6.95, marking an increase of 1.10.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 6.92. This value is within the healthy range. It has increased from 5.88 (Mar 23) to 6.92, marking an increase of 1.04.
For PBDIT Margin (%), as of Mar 24, the value is 23.37. This value is within the healthy range. It has increased from 21.52 (Mar 23) to 23.37, marking an increase of 1.85.
For PBIT Margin (%), as of Mar 24, the value is 19.96. This value is within the healthy range. It has increased from 18.72 (Mar 23) to 19.96, marking an increase of 1.24.
For PBT Margin (%), as of Mar 24, the value is 19.45. This value is within the healthy range. It has increased from 18.23 (Mar 23) to 19.45, marking an increase of 1.22.
For Net Profit Margin (%), as of Mar 24, the value is 14.46. This value exceeds the healthy maximum of 10. It has increased from 14.32 (Mar 23) to 14.46, marking an increase of 0.14.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 14.40. This value is within the healthy range. It has increased from 14.37 (Mar 23) to 14.40, marking an increase of 0.03.
For Return on Networth / Equity (%), as of Mar 24, the value is 15.19. This value is within the healthy range. It has decreased from 15.25 (Mar 23) to 15.19, marking a decrease of 0.06.
For Return on Capital Employeed (%), as of Mar 24, the value is 18.97. This value is within the healthy range. It has increased from 18.75 (Mar 23) to 18.97, marking an increase of 0.22.
For Return On Assets (%), as of Mar 24, the value is 11.70. This value is within the healthy range. It has decreased from 12.15 (Mar 23) to 11.70, marking a decrease of 0.45.
For Total Debt / Equity (X), as of Mar 24, the value is 0.01. This value is within the healthy range. It has decreased from 0.02 (Mar 23) to 0.01, marking a decrease of 0.01.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.89. It has decreased from 0.96 (Mar 23) to 0.89, marking a decrease of 0.07.
For Current Ratio (X), as of Mar 24, the value is 4.78. This value exceeds the healthy maximum of 3. It has decreased from 4.91 (Mar 23) to 4.78, marking a decrease of 0.13.
For Quick Ratio (X), as of Mar 24, the value is 3.19. This value exceeds the healthy maximum of 2. It has decreased from 3.49 (Mar 23) to 3.19, marking a decrease of 0.30.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.21. This value is below the healthy minimum of 4. It has decreased from 1.35 (Mar 23) to 1.21, marking a decrease of 0.14.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 7.22. This value is below the healthy minimum of 20. It has increased from 3.81 (Mar 23) to 7.22, marking an increase of 3.41.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 5.84. This value is below the healthy minimum of 20. It has increased from 3.19 (Mar 23) to 5.84, marking an increase of 2.65.
For Earning Retention Ratio (%), as of Mar 24, the value is 92.78. This value exceeds the healthy maximum of 70. It has decreased from 96.19 (Mar 23) to 92.78, marking a decrease of 3.41.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 94.16. This value exceeds the healthy maximum of 70. It has decreased from 96.81 (Mar 23) to 94.16, marking a decrease of 2.65.
For Interest Coverage Ratio (X), as of Mar 24, the value is 45.43. This value is within the healthy range. It has increased from 43.67 (Mar 23) to 45.43, marking an increase of 1.76.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 29.11. This value is within the healthy range. It has decreased from 30.07 (Mar 23) to 29.11, marking a decrease of 0.96.
For Enterprise Value (Cr.), as of Mar 24, the value is 6,244.01. It has increased from 2,540.86 (Mar 23) to 6,244.01, marking an increase of 3,703.15.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 2.87. This value is within the healthy range. It has increased from 1.37 (Mar 23) to 2.87, marking an increase of 1.50.
For EV / EBITDA (X), as of Mar 24, the value is 12.27. This value is within the healthy range. It has increased from 6.37 (Mar 23) to 12.27, marking an increase of 5.90.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 3.15. This value exceeds the healthy maximum of 3. It has increased from 1.72 (Mar 23) to 3.15, marking an increase of 1.43.
For Retention Ratios (%), as of Mar 24, the value is 92.77. This value exceeds the healthy maximum of 70. It has decreased from 96.18 (Mar 23) to 92.77, marking a decrease of 3.41.
For Price / BV (X), as of Mar 24, the value is 3.33. This value exceeds the healthy maximum of 3. It has increased from 1.83 (Mar 23) to 3.33, marking an increase of 1.50.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 3.15. This value exceeds the healthy maximum of 3. It has increased from 1.72 (Mar 23) to 3.15, marking an increase of 1.43.
For EarningsYield, as of Mar 24, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.08 (Mar 23) to 0.04, marking a decrease of 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Marksans Pharma Ltd as of June 13, 2025 is: 227.17

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of June 13, 2025, Marksans Pharma Ltd is Overvalued by 12.63% compared to the current share price 260.00

Intrinsic Value of Marksans Pharma Ltd as of June 13, 2025 is: 243.38

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of June 13, 2025, Marksans Pharma Ltd is Overvalued by 6.39% compared to the current share price 260.00

Last 5 Year EPS CAGR: 7.14%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 25.67%, which is a positive sign. The company has higher reserves (907.08 cr) compared to borrowings (130.50 cr), indicating strong financial stability. The company has shown consistent growth in sales (342.08 cr) and profit (193.77 cr) over the years.	The stock has a high average Working Capital Days of 102.33, which may not be favorable. The stock has a high average Cash Conversion Cycle of 164.17, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Marksans Pharma Ltd:
1. Net Profit Margin: 14.46%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 18.97% (Industry Average ROCE: 16.67%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 15.19% (Industry Average ROE: 15.2%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 29.11
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 3.19
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 31 (Industry average Stock P/E: 92.21)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.01
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Marksans Pharma Ltd. is a Public Limited Listed company incorporated on 16/04/1992 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24110MH1992PLC066364 and registration number is 066364. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1174.37 Cr. and Equity Capital is Rs. 45.32 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	11th Floor, Grandeur, Mumbai Maharashtra 400053	companysecretary@marksanspharma.com http://www.marksanspharma.com

Management
Name	Position Held
Mr. Mark Saldanha	Chairman & Managing Director
Mrs. Sandra Saldanha	Whole Time Director
Mr. Varddhman V Jain	Whole Time Director
Dr. Sunny Sharma	Non Executive Director
Mr. Seetharama R Buddharaju	Independent Director
Mr. Digant Mahesh Parikh	Independent Director
Mr. Abhinna Sundar Mohanty	Independent Director
Mrs. Shailaja Vardhan	Independent Director

FAQ

What is the intrinsic value of Marksans Pharma Ltd?

Marksans Pharma Ltd's intrinsic value (as of 13 June 2025) is ₹227.17 — 12.63% lower the current market price of 260.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 11,780 Cr. market cap, FY2025-2026 high/low of ₹359/157, reserves of 2,422 Cr, and liabilities of 3,240 Cr.

What is the Market Cap of Marksans Pharma Ltd?

The Market Cap of Marksans Pharma Ltd is 11,780 Cr..

What is the current Stock Price of Marksans Pharma Ltd as on 13 June 2025?

The current stock price of Marksans Pharma Ltd as on 13 June 2025 is 260.

What is the High / Low of Marksans Pharma Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Marksans Pharma Ltd stocks is ₹359/157.

What is the Stock P/E of Marksans Pharma Ltd?

The Stock P/E of Marksans Pharma Ltd is 31.0.

What is the Book Value of Marksans Pharma Ltd?

The Book Value of Marksans Pharma Ltd is 54.4.

What is the Dividend Yield of Marksans Pharma Ltd?

The Dividend Yield of Marksans Pharma Ltd is 0.23 %.

What is the ROCE of Marksans Pharma Ltd?

The ROCE of Marksans Pharma Ltd is 20.1 %.

What is the ROE of Marksans Pharma Ltd?

The ROE of Marksans Pharma Ltd is 16.8 %.

What is the Face Value of Marksans Pharma Ltd?

The Face Value of Marksans Pharma Ltd is 1.00.